Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ACURA PHARMACEUTICALS, INCv327539_ex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

 

 

  

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act Of 1934

 

November 6, 2012

Date of Report (Date of earliest event reported)

  

 

 

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

State of New York 1-10113 11-0853640
(State of Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation)   Identification Number)

 

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

 

(847) 705-7709

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

 

 
 

 

Item 2.02Results of Operations and Financial Condition

 

On November 6, 2012 we issued a press release disclosing the financial results for our third quarter ended September 30, 2012. A copy of our press release is being furnished as Exhibit 99.1 hereto.

 

Item 9.01Financial Statements and Exhibits

 

Exhibit Number   Description
     
99.1   Press Release dated November 6, 2012 announcing financial results for the third quarter ended September 30, 2012

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ACURA PHARMACEUTICALS, INC.
   
  By: /s/ Peter A. Clemens
    Peter A. Clemens
    Senior Vice President & Chief Financial Officer

 

Date:    November 6, 2012

 

 
 

  

Exhibit Index

  

Exhibit Number   Description
     
99.1   Press Release dated November 6, 2012 announcing financial results for the third quarter ended September 30, 2012